Rifabutin with lopinavir/ritonavir in patients coinfected with tuberculosis and HIV in Burkina Faso

Institut de Recherche en Santé (IRSS)0 个研究点目标入组 30 人开始时间: 2013年8月24日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•HIV-1 infected patient
•-Patient aged ¿18 years(minimum) and ¿ 60 years (maximum)
•-Eligible for antiretroviral therapy including Lopinavir/ritonavir regimen (national guideline)
•-Any CD4+
•-New pulmonary tuberculosis (TPM), confirmed or suspected
•-Eligible for antimycobacterial therapy including rifabutin
•-Signed informed consent form
•-For female patients : pregnancy test negative, non lactating, not planning to become pregnant during the follow-up period of the study.

•-Patient doubly infected HIV 1 and 2 or HIV2
•-ALAT > 5 NV
•-creatinine> 3 NV
•-Co-administration of treatment with an absolute contre indication (list to be established)Pregnancy or breastfeeding
•-Presence of medical conditions or other conditions (allergy, intolerance) that contraindicate the administration of a drug in the studioChoice of the clinician to take antiretroviral therapy other than as provided under the Protocol
•-People with MDR or XDR tuberculosis strain from
•-Any medical condition that in the opinion of the investigator poses a risk to the patient

发起方

Institut de Recherche en Santé (IRSS)